BiotechTube
NED Biosystems

NED Biosystems

Cambridge, United States· Est.
nedbiosystems.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

NED Biosystems is pioneering a novel systems-based therapeutic approach to treat complex diseases like cancer and viral infections by combining repurposed, oral drugs at non-toxic doses. Its lead asset, NED-170, is in development for cancer, while NED-260 is a platform-derived program aimed at being a universal antiviral. As a private, pre-revenue Public Benefit Corporation, the company is driven by a mission of global patient access and is led by founder/CEO Rebecca Lambert, supported by a seasoned team and scientific advisory board.

OncologyInfectious Disease

Technology Platform

A systems-based therapeutic platform that combines repurposed, oral agents at low doses to comprehensively target the network behavior of complex diseases (e.g., cancer, viral infections), aiming for efficacy with minimal customary toxicity.

Opportunities

The company's systems-based repurposing approach addresses major unmet needs for safer, more comprehensive cancer treatments and a proactive defense against viral pandemics.
Its oral, outpatient-friendly therapies and Public Benefit Corporation status create a unique value proposition for global accessibility and partnership potential with payers and health systems focused on cost-effective care.

Risk Factors

Key risks include the scientific and regulatory challenge of proving combination efficacy in controlled trials, potential intellectual property limitations with repurposed drugs, and dependence on raising capital as a private, pre-revenue company in a competitive funding landscape.
Execution against large, well-funded competitors in oncology and virology is also a significant risk.

Competitive Landscape

In oncology, NED competes with large pharma and biotech companies developing targeted therapies, immunotherapies, and ADCs. Its differentiation is low-toxicity, oral combination targeting multiple pathways. In antivirals, it faces companies like Gilead and Pfizer, but its proposed broad-spectrum mechanism aims at a unique, pre-pandemic niche. Its repurposing strategy competes with other drug repositioning efforts.

More companies in United States →